VivoSeq
Oncology

Gastric Adenocarcinoma

116

Pipeline Programs↗

28

Active Trials↗

50

Companies Involved↗

Gastric Adenocarcinoma is a highly competitive landscape with 116 programs across 50 companies. The most active players are Shanghai Longyao Biotechnology Inc., Ltd., Arog Pharmaceuticals, Inc., Gynecologic Oncology Group. 4 therapies are approved with 35 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

73/100

Pipeline Velocity

36/100

Mech. Concentration

13/100

Completion Rate

78/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai Longyao Biotechnology Inc., Ltd.

1 program

Phase 1A

Arog Pharmaceuticals, Inc.

1 program

Phase 1G

Gynecologic Oncology Group

1 program

Phase 1B

Beijing Biohealthcare Biotechnology Co.,Ltd

2 programs

Phase 2Basilea Pharmaceutica logo

Basilea Pharmaceutica

2 programs

Phase 2G

Glaxo Dba Glaxosmithkline

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical4

Trastuzumab

Organon and Co

TAS 102

Taiho Oncology, Inc.

Pabolizumab

Fudan University

Pimonidazole Hydrochloride

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 16

Atezolizumab

Roche

Mitomycin C

Gynecologic Oncology Group

FLOT Alone

AstraZeneca

LY011

Shanghai Longyao Biotechnology Inc., Ltd.

Crenolanib

Arog Pharmaceuticals, Inc.

Phase 267

Serplulimab

Shanghai Henlius Biotech

Ipatasertib

Roche

Toripalimab

Coherus Oncology, Inc.

Capmatinib

Novartis

Surufatinib

Hutchison Medipharma Limited

Phase 335

Docetaxel

Avyxa

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Sintilimab

Innovent Biologics (Suzhou) Co. Ltd.

Paclitaxel

Teva

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Approved4

Tucatinib

Pfizer

Selumetinib

AstraZeneca

Carbamazepine

Novartis

Imatinib

Novartis

Analysis

Modality Breakdown

75%

Small molecule

106 of 141 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody3323%Antibody–drug conjugate1<1%Protein / enzyme1<1%

Small molecule leads; the ring shows all 141 classified programs, each share of the total. Modality classified for 96% of 151 pipeline programs.

Analysis

Trial Status

109

clinical trials

Completed38 · 35%
Unknown status32 · 29%
Not yet recruiting12 · 11%
Recruiting11 · 10%
Terminated8 · 7%
Active, not recruiting5 · 5%
Other3 · 3%

Clinical Trials

Trial Activity

109 trials

Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma
Recruiting·RRenmin Hospital of Wuhan University·Phase 2·NCT05563012·29 enrolled
Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma
Recruiting·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT07270991·324 enrolled
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 1·NCT07059299·18 enrolled
Hypoxia Driven Metabolic Response in Oesophagogastric Adenocarcinoma
Recruiting·IImperial College London·N/A·NCT06669663·120 enrolled
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05977998·30 enrolled
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
Recruiting·—·Phase 2·NCT05872685·314 enrolled
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
Recruiting·PPeking University Cancer Hospital & Institute·N/A·NCT04047953·95 enrolled
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma
Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 1/2·NCT06731803·36 enrolled
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT06340711·27 enrolled
A Multicenter, Randomized, Controlled, Open-label Phase III Clinical Trial Evaluating the Efficacy and Safety of JS107 in Combination With Toripalimab and Chemotherapy Versus Sintilimab in Combination With Chemotherapy as First-line Treatment for CLDN18.2-positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·NNingBo Junyan Hongshi Biosciences Co., Ltd·Phase 3·NCT07584135·600 enrolled
A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Recruiting·TToray Industries, Inc·Phase 2·NCT06038578·146 enrolled
A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma
Active, not recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT07257575·138 enrolled
Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04523818·25 enrolled
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04209686·36 enrolled
Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.
Active, not recruiting·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT04006262·32 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)